JP2015519398A - 治療用製剤および処置の方法 - Google Patents

治療用製剤および処置の方法 Download PDF

Info

Publication number
JP2015519398A
JP2015519398A JP2015517316A JP2015517316A JP2015519398A JP 2015519398 A JP2015519398 A JP 2015519398A JP 2015517316 A JP2015517316 A JP 2015517316A JP 2015517316 A JP2015517316 A JP 2015517316A JP 2015519398 A JP2015519398 A JP 2015519398A
Authority
JP
Japan
Prior art keywords
formulation
hydralazine
weight
amount
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015517316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519398A5 (https=
Inventor
ルイス，パメラ・エイ
ウォーラー，ウィリアム・エイチ
Original Assignee
マククリア・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49715792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015519398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by マククリア・インコーポレイテッド filed Critical マククリア・インコーポレイテッド
Publication of JP2015519398A publication Critical patent/JP2015519398A/ja
Publication of JP2015519398A5 publication Critical patent/JP2015519398A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015517316A 2012-06-11 2013-06-06 治療用製剤および処置の方法 Ceased JP2015519398A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261658304P 2012-06-11 2012-06-11
US61/658,304 2012-06-11
PCT/US2013/044617 WO2013188217A1 (en) 2012-06-11 2013-06-06 Therapeutic formulation and methods of treatment

Publications (2)

Publication Number Publication Date
JP2015519398A true JP2015519398A (ja) 2015-07-09
JP2015519398A5 JP2015519398A5 (https=) 2016-07-21

Family

ID=49715792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517316A Ceased JP2015519398A (ja) 2012-06-11 2013-06-06 治療用製剤および処置の方法

Country Status (9)

Country Link
US (2) US9254287B2 (https=)
JP (1) JP2015519398A (https=)
KR (1) KR20150032552A (https=)
CN (1) CN104768533A (https=)
AU (1) AU2013274582A1 (https=)
HK (1) HK1212225A1 (https=)
SG (1) SG11201408230VA (https=)
TW (1) TW201410245A (https=)
WO (1) WO2013188217A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164419A1 (en) * 2014-04-22 2015-10-29 Acucela Inc. Pupillometric assessment of retinal pharmacodynamics and responses therefrom
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
WO2019079515A1 (en) * 2017-10-17 2019-04-25 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN-BASED TREATMENT IN AGE-RELATED MACULAR DEGENERATION (AMD)
BR112020013238A2 (pt) 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
US12109211B2 (en) 2021-12-29 2024-10-08 Endo Operations Limited Hydralazine compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02502635A (ja) * 1987-01-23 1990-08-23 ザ・ゼネラル・ホスピタル・コーポレイション 緑内障、水頭症、および脳水腫（頭蓋液量異常）治療用のアトリオペプチン、グアニル酸シクラーゼ賦活物質、およびホスホジエステラーゼ阻害物質
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP2008540528A (ja) * 2005-05-12 2008-11-20 ザ テキサス エー アンド エム ユニバーシティー システム 治療用組成物および方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
US4865599A (en) 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
FI873429L (fi) 1986-08-18 1988-02-19 Houston Biotechnology Oftalmologiska kompositioner foer behandling av nervdegenerationer.
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5252607A (en) 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
TW264385B (https=) * 1993-05-14 1995-12-01 Taiho Pharmaceutical Co Ltd
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
EP0911027A4 (en) 1996-04-26 2000-11-29 Fujisawa Pharmaceutical Co THE DIHYDROPYRIDINE CONTAINS TO IMPROVE THE CIRCULATION OF THE EYE-SURROUNDING TISSUE
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
CA2270119A1 (en) 1996-10-28 1998-05-07 Senju Pharmaceutical Co., Ltd. Drugs for ameliorating ocular circulatory disorders
AU741525B2 (en) 1998-03-06 2001-12-06 Board Of Regents, The University Of Texas System Composition and method for treating macular disorders
US6028099A (en) 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
EP1161686A2 (en) 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
JP4599292B2 (ja) 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
JP2004250347A (ja) 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1814535A4 (en) 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
JP2008531697A (ja) * 2005-02-28 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強基を含む心血管化合物、組成物および使用法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02502635A (ja) * 1987-01-23 1990-08-23 ザ・ゼネラル・ホスピタル・コーポレイション 緑内障、水頭症、および脳水腫（頭蓋液量異常）治療用のアトリオペプチン、グアニル酸シクラーゼ賦活物質、およびホスホジエステラーゼ阻害物質
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP2008540528A (ja) * 2005-05-12 2008-11-20 ザ テキサス エー アンド エム ユニバーシティー システム 治療用組成物および方法

Also Published As

Publication number Publication date
US20130331393A1 (en) 2013-12-12
US20160151368A1 (en) 2016-06-02
AU2013274582A1 (en) 2015-01-22
TW201410245A (zh) 2014-03-16
SG11201408230VA (en) 2015-01-29
WO2013188217A1 (en) 2013-12-19
KR20150032552A (ko) 2015-03-26
CN104768533A (zh) 2015-07-08
US9694010B2 (en) 2017-07-04
US9254287B2 (en) 2016-02-09
HK1212225A1 (en) 2016-06-10

Similar Documents

Publication Publication Date Title
Baudouin et al. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers
Kawase et al. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study
Kapin et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac
JP7297308B2 (ja) 眼科用医薬組成物及びそれに関する使用
US9694010B2 (en) Therapeutic formulation and methods of treatment
Labbé et al. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study
Penha et al. Effects of subretinal injections of indocyanine green, trypan blue, and glucose in rabbit eyes
RU2700927C2 (ru) Офтальмологическая композиция, содержащая циклоспорин и трегалозу
KR20070094600A (ko) 안질환 치료제
Balaiya et al. Comparative in vitro safety analysis of dyes for chromovitrectomy: indocyanine green, brilliant blue green, bromophenol blue, and infracyanine green
Zhao et al. Multimodal fundus imaging of sodium iodate-treated mice informs RPE susceptibility and origins of increased fundus autofluorescence
JP7615139B2 (ja) 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤
Kaldırım et al. Efficacy of hyperbaric oxygen therapy on central corneal thickness, intraocular pressure, and nerve fiber layer in patients with type 2 diabetes: A prospective cohort study
Fernandez-Garcia et al. Corneal thickness differences between sexes after oxybuprocaine eye drops
Okka et al. Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys
Perez-Bermejo et al. Corneal thickness response after anesthetic eye drops: our own results and meta‐analysis
Szumny et al. The influence of new beta-adrenolytics nebivolol and carvedilol on intraocular pressure and iris blood flow in rabbits
Heilweil et al. Normal physiological and pathophysiological effects of trypan blue on the retinas of albino rabbits
US11045435B2 (en) Methods for treating ocular diseases
Heywood The eye
NZ518164A (en) Rivastigmine for the treatment of ocular disorders
US20060194874A1 (en) Use of propionyl l-carnitine for the preparation of a medicament for the treatment of glaucoma
EP3682867B1 (en) Lutein-containing ophthalmic composition
Bastola et al. SPG302 protects retinal ganglion cells and preserves visual function by preserving synaptic activity in a mouse model of glaucoma
TWI766565B (zh) 用於治療眼疾的組合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170914

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171107

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20180327